Fluorescence-guided Resection in Breast Cancer
This is an explorative phase II study to investigate the suitability of PD L 506 in the specific intra-operative detection of breast tumour tissue.
Breast Tumour
DRUG: PD L 506
Fluorescence intensity in breast cancer tissue, 3 h after intake of study medication
Laboratory data and adverse events, 14 days
This is an explorative phase II study to investigate the suitability of PD L 506 in the specific intra-operative detection of breast tumour tissue.